Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Rademikibart · CBP-201

Other · developed by Connect Biopharm LLC

Phase 2 Most advanced trial

CNTB Developer

1 Registered trials

What is Rademikibart?

Rademikibart (CBP-201) is an agent given as a single 300 mg intravenous push over about 2 minutes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CBP-201
Drug type: Other
Therapy area: Respiratory
Developer: Connect Biopharm LLC (CNTB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: NWV8DWU7QM

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07705737	Phase 2	Asthma Acute	Recruiting	CNTB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Asthma AcuteCOPD Exacerbation Acute

More from Connect Biopharm LLC

CBP-174 Phase 1 CBP-201 Phase 3 CBP-307 Phase 2

Sources

ClinicalTrials.gov NCT07705737

Updated Oct 11, 2026. Something wrong or missing? Report it on the CNTB page.

Follow CNTB, the company behind Rademikibart

See CNTB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CNTB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z